Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. has called its annual general meeting for 18 June 2026 at 16:00 CEST in Amsterdam, with a record date of 21 May 2026. Shareholders on the record date may attend and vote in person or by proxy, with detailed procedures for registered and beneficial owners.
Key agenda items include adopting the statutory annual accounts for the year ended 31 December 2025, discussing dividend and reservation policy, and granting discharge to directors. Shareholders will vote on reappointing Harpreet Singh Jasuja as executive director and two non-executive directors through the 2029 AGM, extending the Board’s authority for share repurchases for 18 months from the AGM, and approving a 2026 stock option and incentive plan covering up to 6,448,836 ordinary shares. Appointment of PricewaterhouseCoopers Accountants N.V. as auditor for financial year 2026 is also proposed.
Immatics N.V. reports extensive early‑stage clinical data across its PRAME‑ and MAGEA4/8‑targeted pipeline, highlighting activity in multiple hard‑to‑treat solid tumors. The 6‑K centers on updated Phase 1/1b results for IMA203CD8, IMA401 and anzu‑cel presented at the 2026 ASCO meeting.
For anzu‑cel in advanced melanoma, confirmed objective response rate was 56% (18/32) with overall response rate 64% (21/33) and disease control rate 91% (30/33). Median duration of response reached 14.6 months, median progression‑free survival 6.1 months and median overall survival 16.2 months, with some responses exceeding three years.
IMA203CD8 showed dose‑dependent anti‑tumor activity in heavily pretreated gynecologic cancers and synovial sarcoma, with manageable cytokine release syndrome and no treatment‑related Grade 5 events. IMA401, a MAGEA4/8 TCR bispecific, demonstrated a favorable tolerability profile and clinical activity at the 1–2 mg recommended Phase 2 dose, supporting a new IMA401/IMA402 combination cohort in squamous non‑small cell lung cancer. All datasets are preliminary and drawn from ongoing early‑phase trials.
Immatics N.V. states that Vestal Point Capital and Ryan Wilder report ownership of 6,175,000 Ordinary Shares, representing 4.6% of the class.
The filing cites 134,071,432 Ordinary Shares outstanding as of December 31, 2025 (from the company's Form 20-F filed March 5, 2026). The shares are directly held by the Vestal Point Fund and Account; Mr. Wilder is identified as the investment manager's CIO and Managing Partner.
The Toronto-Dominion Bank reported beneficial ownership of 5.5% of Immatics N.V., holding 7,436,342 ordinary shares as of 03/31/2026. The filing shows the bank has sole voting and sole dispositive power over these shares.
IMMATICS NV ownership disclosure: T. Rowe Price Investment Management, Inc. filed Amendment No. 4 to report beneficial ownership of 21,652,162 shares of common stock, representing 16.1% of the class. The filing lists 21,600,896 shares with sole voting power and 21,652,162 with sole dispositive power. The filing includes a formal disclaimer denying beneficial ownership in the same submission.
Immatics N.V. files an Amendment No. 4 to a Schedule 13G/A reporting shared beneficial ownership of 12,869,340 shares (representing 9.6% of the class). The percentage is calculated using 134,071,432 shares outstanding as of December 31, 2025, as reported in the company's Form 20-F.
The statement is filed by RTW Investments, LP and Roderick Wong, M.D.; both report shared voting and dispositive power over the noted shares held by certain RTW funds. The filing incorporates a joint filing agreement by reference.
Immatics N.V. reported a wider net loss of €57.8 million for the three months ended March 31, 2026, compared with €39.9 million a year earlier, or €0.43 loss per share. Revenue from collaboration agreements declined to €7.6 million from €18.6 million, mainly due to lower cost-based progress on the Moderna and BMS partnerships. Research and development expenses rose to €59.2 million, driven by increased spending on PRAME-focused TCR cell therapies and bispecifics, particularly the SUPRAME Phase 3 trial for anzu-cel. Immatics ended the quarter with cash, cash equivalents and other financial assets totaling €453.6 million ($521.5 million), and projects its cash reach into 2028 while advancing multiple PRAME-targeted clinical programs and preparing for a potential first commercial launch of anzu-cel in 2027.
Immatics N.V. filed a report noting that all of its submitted scientific abstracts were selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Company will deliver four talks covering both its PRAME-directed T-cell therapies and its T-cell receptor-based bispecifics.
Presentations will highlight patient-level response data in advanced melanoma for anzutresgene autoleucel (anzu-cel), Phase 1 results for IMA203CD8 in ovarian cancer, Phase 1 PRAME T-cell therapy data in synovial sarcoma, and first-in-human results for the MAGEA4/8 bispecific IMA401 in recurrent or refractory solid tumors. Immatics positions itself as a global leader in precision targeting of PRAME across multiple cancer indications.
Immatics N.V. reports that an abstract describing a pediatric case treated with its PRAME-directed TCR cell therapy has been accepted as a late-breaking poster at the AACR Annual Meeting 2026 in San Diego.
The case involves a 17-year-old with PRAME-positive advanced metastatic nephroblastoma who had exhausted standard treatment options. After receiving a TCR T-cell therapy using Immatics’ PRAME TCR encoded by the IMA203CD8 lentiviral vector, the patient achieved deep anti-tumor remission, first seen three months after infusion and ongoing at six months of follow-up. Imaging showed marked regression across lung, liver, brain and abdominal lesions, and liquid biopsy no longer detected tumor-derived DNA, indicating molecular remission. Cytokine release syndrome occurred but was described as manageable and resolved with multi-modal anti-cytokine therapy and corticosteroids. Immatics highlights PRAME as a target expressed in more than 50 cancers and plans to evaluate its PRAME TCR T-cell therapies in pediatric patients, including assessing a potential first-in-pediatrics Phase 1/2 basket study for relapsed or refractory PRAME-expressing solid tumors at KiTZ in Heidelberg.
Immatics N.V. Chief Development Officer Carsten Alexander Johannes Reinhardt filed a Form 3 reporting his initial ownership in the company. He holds 47,781 Ordinary Shares directly, a series of stock options to buy additional Ordinary Shares at exercise prices ranging from $1.06 to $11.00 with expirations between 2027 and 2036, and 40,000 restricted stock units that vest in four equal annual installments beginning on January 8, 2026.